MLAB vs NEOG vs LFUS vs NOVT vs RGEN

For growth investors, Repligen Corporation (RGEN) is the stronger pick with 16.

4% revenue growth year-over-year, versus -3. 2% for Neogen Corporation (NEOG). Novanta Inc. (NOVT) offers the better valuation at 92. 7x trailing P/E (38. 2x forward), making it the more compelling value choice. Analysts rate Littelfuse, Inc. (LFUS) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novanta Inc.

(NOVT) is the cheapest at 92. 7x versus Repligen Corporation at 147. 0x. On forward P/E, Mesa Laboratories, Inc. is actually cheaper at 11. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Littelfuse, Inc.

(LFUS) delivered a total return of +71. 8%, compared to -80. 6% for Neogen Corporation (NEOG). Over 10 years, the gap is even starker: NOVT returned +853. 7% versus NEOG's -49. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Repligen Corporation (RGEN) is the lower-risk stock at 1.

76β versus Novanta Inc. 's 2. 02β — meaning NOVT is approximately 15% more volatile than RGEN relative to the S&P 500. On balance sheet safety, Novanta Inc. (NOVT) carries a lower debt/equity ratio of 26% versus 114% for Mesa Laboratories, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Repligen Corporation (RGEN) is pulling ahead at 16.

4% versus -3. 2% for Neogen Corporation (NEOG). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, NEOG leads at 19. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Repligen Corporation (RGEN) is the more profitable company, earning 6.

6% net margin versus -122. 1% for Neogen Corporation — meaning it keeps 6. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NOVT leads at 11. 9% versus 1. 1% for NEOG. At the gross margin level — before operating expenses — MLAB leads at 62. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Mesa Laboratories, Inc.

(MLAB) trades at 11. 7x forward P/E versus 64. 3x for Repligen Corporation — 52. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RGEN: 32. 9% to $168. 00.

In this comparison, LFUS (0.

7% yield), MLAB (0. 6% yield) pay a dividend. NEOG, NOVT, RGEN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Littelfuse, Inc.

(LFUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 7% yield, +317. 6% 10Y return). Neogen Corporation (NEOG) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LFUS: +317. 6%, NEOG: -49. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MLAB (Technology) and NEOG (Healthcare) and LFUS (Technology) and NOVT (Technology) and RGEN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MLAB is a small-cap quality compounder stock; NEOG is a small-cap quality compounder stock; LFUS is a mid-cap quality compounder stock; NOVT is a small-cap quality compounder stock; RGEN is a small-cap high-growth stock. MLAB, LFUS pay a dividend while NEOG, NOVT, RGEN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.